Dual Antiplatelet Therapy with Parenteral P2Y(12) Inhibitors: Rationale, Evidence, and Future Directions

Dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and an inhibitor of the platelet P2Y(12) receptor for ADP, remains among the most investigated treatments in cardiovascular medicine. While a substantial amount of research initially stemmed from the observations of late and...

Descripción completa

Detalles Bibliográficos
Autores principales: Alagna, Giulia, Mazzone, Paolo, Contarini, Marco, Andò, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144071/
https://www.ncbi.nlm.nih.gov/pubmed/37103042
http://dx.doi.org/10.3390/jcdd10040163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144071/
https://www.ncbi.nlm.nih.gov/pubmed/37103042
http://dx.doi.org/10.3390/jcdd10040163

Ejemplares similares